Translate Bio logo

Translate Bio

Translate Bio is pioneering the translation of RNA science into therapeutics promoting healthy gene expression. Translate Bio(initially RaNa therapeutics) (NASDAQ: TBIO) is a next generation biotechnology company focused on the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”TBIO” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://translate.bio
Founded2010
Disease Focus
Development Stage
STOCK CODENASDAQ: TBIO
Address
29 Hartwell Ave, MA, 02421
Lexington
United States
Email
Contact Number
+1 617-945-7361

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/translate-bio” connections=”true” suffix=””]

Translates proprietary mRNA therapeutic(MRT) platform creates mRNA that encodes functional proteins, which on delivery to target cells are recognised of its own and are translated resulting in restoration or augumentation of protein function to treat or prevent disease. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.

In 2013, Santaris Pharma granted Translate Bio rights to use Santaris locked nucleic acid (LNA) technology to discover and develop RNA-targeted therapies against up to 10 undisclosed targets from Translate Bio.

In July 2015, Translate Bio raised $55 Mn USD in Series B financing, led by Merck Ventures & The Baupost Group, LLC. Earlier in 2012, it raised $20.7 Mn in Series A round co-led by Atlas Venture, SR One, Monsanto and Partners Innovation Fund.